Prostate Cancer Clinical Trial
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
The purpose of this study is to test the safety of a new type of IG-IMRT called "ultra-hypofractionated IG-IMRT" where a higher dose of radiation is given to the tumor during each treatment day. Since higher doses of radiation are used each day, the total number of treatment days needed to complete this type of radiation is only five instead of the 45-48 treatments currently used. Treatment takes place every other day and is complete after 2 weeks. If the patient decides to get this treatment, they will come in for 5 treatments. This is different from the 48 treatments they would get normally.
Eligibility is not restricted to MSKCC to confirm biopsy/diagnosis. Participating institution testing is sufficient.
Low and intermediate risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines.
Low risk patients will be defined as:
PSA < or = to 10 ng/ml and
Gleason score = 6 and
Clinical Stage < or = to T2a
Intermediate risk patients will be defined as:
PSA 10-20 ng/ml or
Gleason score = 7 or
Clinical stage T2b/T2c
Additionally, patients will be required to meet the following criteria:
Age > or = to 18
KPS > or = to 70
Pre-treatment endorectal coil MRI or CT (MRI preferred) at MSKCC showing no definite evidence of radiographic T3, T4, or N1 disease
Prostate size < or = to 60 cc
International Prostate Symptom Score < or = to 15
Prior androgen deprivation therapy for prostate cancer
Elective pelvic lymph node irradiation
KPS < 70
Pelvic MRI or CT (MRI preferred) evidence of radiographic T3, T4 or N1 disease
Presence of distant metastasis as determined by:
o alkaline phosphatase > or = to ULN or
whole body bone scan positive for osseous metastases
Prior history of transurethral resection of the prostate
Prior history of chronic prostatitis
Prior history of urethral stricture
Prior history of pelvic irradiation
History of inflammatory bowel disease
Unable to give informed consent
Unable to complete quality of life questionnaires Abnormal complete blood count. Any of the following
Platelet count less than 75,000/ml
Hb level less than 10 gm/dl
WBC less than 3.5/ml
Abnormal renal function tests (creatinine > 1.5)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Bronx New York, 10467, United States
Commack New York, 11725, United States
Harrison New York, 10604, United States
New York New York, 10065, United States
Rockville Centre New York, , United States
Sleepy Hollow New York, , United States
Uniondale New York, 11553, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.